Mirus | GenomeWeb

Mirus

Mirus Bio has introduced the TransIT-X2 dynamic delivery system.
According to the company, the polymeric nucleic acid-delivery system can be used for independent or simultaneous delivery of DNA and siRNA to a variety of cell types.

Arrowhead Research's top executive this week broke out details on the company's efforts to move its RNAi-based hepatitis B virus treatment ARC-520 into the clinic, stating that the firm will run two phase I trials in order to speed up the generation of key human data.

Arrowhead Research last week released new preclinical data on its lead drug candidate, the hepatitis B virus treatment ARC-520, reporting that the agent could trigger up to multi-log reductions in the levels of circulating viral antigens, while lowering levels of the virus' repli

Arrowhead Research announced this week that it has signed a RNAi services agreement with Germany's Axolabs, bringing together the US and European halves of Roche's former RNA therapeutics operations that were divested by the biopharmaceutical giant in 2010.

Ivanka Trump and Secretary of Education Betsy DeVos call on girls to pursue STEM careers, the Associated Press reports.

Some science companies will be taking part in next month's March for Science, Fortune reports.

In Genome Research this week: longitudinal study of Burkholderia cenocepacia isolates from cystic fibrosis patients, long-read assembly approach, and more.

Shale oil companies are turning to DNA sequencing to find spots to drill, Reuters reports.